Non-Small Cell Lung Cancer Metastatic
Conditions
Keywords
Non small cell lung cancer, Oligo-metastasis, EGFR activating mutation, Radiotherapy
Brief summary
In this phase II trial with single arm, we aim to investigate the clinical efficacy and toxicity profile of local radiotherapy on all disease sites for EGFR-mutant oligo-metastatic NSCLC (no more than 3 metastatic lesions) who did not experience disease progression after at least 3 months of TKI therapy.
Detailed description
Tyrosine kinase inhibitor (TKI) has been widely accepted as the first-line therapy for stage IV NSCLC with active mutation of EGFR. Olio-metastasis is a disease status between localized and extended status of disease, namely with the limited number of lesions, which is generally defined as ≤ 5. A couple of phase II studies have shown that consolidation local management was able to prolong the local-regional tumor control and might further improve overall survival (OS) for oligo-metastatic NSCLC who have gained disease control from systemic therapy. However, there is lack of data regarding whether local radiotherapy (RT) could improve progression free survival (PFS) and OS for NSCLC with active EGFR mutation who have benefited from TKI. In this phase II trial with single arm, we aim to investigate the clinical efficacy and toxicity profile of local radiotherapy on all disease sites for EGFR-mutant oligo-metastatic NSCLC (no more than 3 metastatic lesions) who did not experience disease progression after at least 3 months of TKI therapy.
Interventions
RADIATIONLocal radiation therapy
Local radiotherapy on all sites of disease including primary and metastatic lesions
Sponsors
Chinese Academy of Medical Sciences
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
* Age ≥18 and ≤75; * ECOG performance status 0-1; * Patients must provide study specific informed consent prior to study entry; * Pathologically or cytologically diagnosed as NSCLC; * EGFR activating mutation to TKI approved by histology, cytology or circulation tumor DNA; * Stage IV NSCLC with ≤ 3 metastatic lesions (AJCC, 8th ed.) confirmed by meticulous radiographic examination. Brain MRI and 18F PET/CT is strongly recommended unless there is a contraindication; * Patients have received≥3 months of TKI therapy and do not received disease progression; * HB ≥ 10.0 g/dL; * Absolute number of neutrophil granulocyte ≥ 1.5 × 109/L; * Absolute number of PLT ≥ 100 × 109/L; * Total bilirubin ≤ 1.5 folds of the maximum extent; * ALT and AST ≤ 2.0 folds of the maximum extent; * Cr ≤ 1.25 folds of the maximum extent and Ccr ≥ 60mLl/min.
Exclusion criteria
* Patients have received thoracic radiotherapy before; * Malignant pleural effusion, pericardial effusion or peritoneal effusion; * Patients have severe pulmonary comorbidity, such as ILD, COPD or other active pulmonary disease; * Any unstable systemic disease including active infection, uncontrolled hypertension, unstable angina, CHF (NYHA ≥ II), MI within 6 months of enrollment, severe arrhythmia requiring medication，hepatic, nephric or metabolic disease; * HIV infection； * Pregnancy or lactation women; * ECOG status ≥2； * Mixed SCLC component; * Other factors that is considered ineligible.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Progression free survival | 1 year | Duration between the first date of TKI administration and disease progression or last follow-up |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Overall response | 1 month after RT | Post-RT response compared with the baseline status at the first data of TKI administration |
| Overall survival | 2 year | Duration between the first date of TKI administration and any cause of death or last follow up |
| Time to progression of initial lesions | 1 year | Duration between the first date of TKI administration and the progression of the initial lesions or last follow up |
| Time to appearance of new metastatic lesions | 1 year | Duration between the first date of TKI administration and the occurrence of new lesions or last follow up |
| Treatment related toxicity | 1 year | Number of Participants With Treatment-Related Adverse Events as Assessed by CTCAE v4.0 |
| EORTC Quality of life | 1 year | Quality of life evaluation using EORTC questionnaires |
Countries
China
Contacts
Primary ContactJingbo Wang, MD
Backup ContactXiaotong Lu, MD
Outcome results
None listed